1-5 of 5
Lihe Su
Close
Sort by
Journal Articles

Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy

Paul Rennert, Lihe Su, Lan Wu, Roy Lobb, Christine Ambrose
Journal: Blood
Blood (2021) 138 (Supplement 1): 1713.
https://doi.org/10.1182/blood-2021-153295
Published: 2021
Journal Articles

A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo

Paul Rennert, PhD, Lihe Su, PhD, Fay Dufort, PhD, Alyssa Birt, MS, Tom Sanford, Lan Wu, PhD, Christine Ambrose, PhD, Roy Lobb, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 252.
https://doi.org/10.1182/blood-2019-130654
Published: 2019
Journal Articles

CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies

Paul Rennert, PhD, Christine Ambrose, PhD, Lihe Su, PhD, Fay Dufort, PhD, Lan Wu, PhD, Andreas Hombach, PhD, Hinrich Abken, PhD, Roy Lobb, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4457.
https://doi.org/10.1182/blood.V130.Suppl_1.4457.4457
Published: 2017
Journal Articles

CDP7657, and Other Anti-CD40L Antibody Formats Lacking a Functional Fc Region, Do Not Cause Platelet Activation In Vitro

Ali Amirkhosravi, PhD., Todd Meyer, PhD., Olivier Harari, PhD., Linda Burkly, PhD., Lihe Su, PhD., Yen-Ming Hsu, PhD., Timothy Bourne, PhD., Ian Wakefield, PhD., Christopher Peters, PhD., Anthony Shock, PhD., John Francis, PhD
Journal: Blood
Blood (2010) 116 (21): 5128.
https://doi.org/10.1182/blood.V116.21.5128.5128
Published: 2010
Journal Articles

Platelet Activation by a Humanized Monoclonal CD40 Ligand (CD40L) Antibody.

Todd Meyer, PhD, Ali Amirkhosravi, Ph.D., Theresa Robson, B.A., Mildred Amaya, M.S., Desai Hina, M.S., Lihe Su, Ph.D., Yen-Ming Hsu, Ph.D., Florian Langer, M.D., John L. Francis, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 1516.
https://doi.org/10.1182/blood.V108.11.1516.1516
Published: 2006